[ad_1]
Greater than 30,000 individuals will descend on Barcelona, Spain, this week for the 2024 European Society for Medical Oncology (ESMO) Congress, which runs from September 13 to 17.
Because the assembly’s start in 1975 with about 100 oncologists, it has grown to one of many world’s most essential oncology occasions. This yr, the assembly will function greater than 2000 abstracts, nearly 100 of them late-breaking, offered throughout practically 300 classes.
Ann Partridge, MD, a breast cancer specialist on the Dana-Farber Most cancers Institute, Boston, is wanting ahead to attending the assembly and listening to what’s new.
ESMO “offers a useful alternative to remain up to date on the most recent advances in most cancers analysis, community with main world consultants, and convey again cutting-edge data to enhance affected person care,” Partridge advised Medscape.
Social media can be abuzz with oncologists giving their prime picks in anticipation of the assembly shows in addition to pharmaceutical firms and educational researchers selling their newest findings.
Two of the three presidential sessions this yr will spotlight “practice-changing trials.”
This can embrace general survival outcomes from the part 3 KEYNOTE-522 (LBA4) in ladies with high-risk triple-negative breast most cancers who obtained pembrolizumab (Keytruda) or placebo alongside chemotherapy within the neoadjuvant setting, adopted by adjuvant pembrolizumab or placebo.
One other trial — the part 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 examine — will discover general survival knowledge in sufferers receiving pembrolizumab plus chemoradiotherapy to deal with high-risk domestically superior cervical cancer.
“It is putting,” Rebecca Dent, MD, ESMO’s scientific chair this yr, advised Medscape Medical Information, “that we now observe in harder-to-treat cancers reminiscent of bladder, cervical, and triple damaging breast most cancers, long-term enhancements utilizing immune-checkpoint inhibitors within the neoadjuvant setting much like what we’ve seen, as an illustration, in lung most cancers.”
The findings can provide “physicians confidence of their each day observe,” added Dent, a breast oncologist in Singapore.
New this yr, Dent mentioned, shall be a presidential session titled “Eyes to the Future” on September 16. The session covers methods for incorporating synthetic intelligence into diagnostics, countering drug resistance, and bettering organ preservation with systemic therapies.
Different themes on the assembly embrace new analysis on novel mRNA vaccines, mixture remedies for central nervous system tumors, use of antibody-drug conjugates past breast most cancers, the rise of most cancers in younger individuals, and problematic epigenetic adjustments and find out how to counter them.
Partridge, who’s receiving the ESMO Award this yr, is wanting ahead to “a lot of very thrilling” breast most cancers abstracts being offered, together with two papers she co-authored on breastfeeding in breast most cancers. One of many research focuses on ladies with hormone receptor–optimistic tumors who take a break from endocrine remedy and the opposite explores breastfeeding after being recognized with BRCA-positive tumors.
Partridge mentioned she can be anticipating updates concerning the potential to make use of fewer however increased doses of radiation to chop the variety of classes wanted to deal with early breast most cancers and hopefully cut back affected person burden.
“The aim needs to be for everybody to step exterior their consolation zone and find out about one thing new,” Partridge mentioned.
[ad_2]
Source link
